Link Cell Therapies

Link Cell Therapies is a South San Francisco clinical-stage cell therapy company founded by Stanford investigators Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital, working on the development of safe and effective CAR T agents for patients with solid tumors. The company's logic-gate technology produces AND-gate CAR T cells that require co-expression of two cancer targets before driving cell cytotoxicity, giving greater tumor specificity than existing logic-gate approaches and aiming to avoid off-tumor toxicity. Alongside additional platforms under development, Link is advancing therapeutic programs across solid tumors and certain hematologic cancers, including a dual-targeting AND-gated CAR program (LNK001) directed at clear cell renal cell carcinoma, and in January 2026 entered a strategic collaboration with Johnson & Johnson to develop logic-gate LINK CAR T therapies. Link Cell Therapies publishes no public API, developer portal, or machine-readable interface; this profile captures company identity and probed public-surface posture only.

Link Cell Therapies is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Life Sciences, Cell Therapy, and CAR T.

Link Cell Therapies’ developer surface includes product news and 11 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.8/100 minimal ▬ flat Agent 4/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyLife SciencesCell TherapyCAR TOncologyImmunotherapyPrecision MedicineClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 10.8/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 4/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/link-cell-therapies: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 2

MCP servers, agent skills, and machine-readable catalogs

WellKnown

WellKnown

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 6

The organization behind the API

Website

About

News

Careers

Investors

LinkedIn

Other 1

Properties that don't map to a standard resource type

Team

Team

Source (apis.yml)

aid: link-cell-therapies
name: Link Cell Therapies
description: Link Cell Therapies is a South San Francisco clinical-stage cell therapy company founded by Stanford investigators
  Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital, working on the development of safe and effective
  CAR T agents for patients with solid tumors. The company's logic-gate technology produces AND-gate CAR T cells that require
  co-expression of two cancer targets before driving cell cytotoxicity, giving greater tumor specificity than existing logic-gate
  approaches and aiming to avoid off-tumor toxicity. Alongside additional platforms under development, Link is advancing therapeutic
  programs across solid tumors and certain hematologic cancers, including a dual-targeting AND-gated CAR program (LNK001)
  directed at clear cell renal cell carcinoma, and in January 2026 entered a strategic collaboration with Johnson & Johnson
  to develop logic-gate LINK CAR T therapies. Link Cell Therapies publishes no public API, developer portal, or machine-readable
  interface; this profile captures company identity and probed public-surface posture only.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://linkcelltx.com/wp-content/uploads/2023/04/linkcell-logo.png
url: https://raw.githubusercontent.com/api-evangelist/link-cell-therapies/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- wing-venture-capital
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Life Sciences
- Cell Therapy
- CAR T
- Oncology
- Immunotherapy
- Precision Medicine
- Clinical Stage
apis: []
common:
- type: DomainSecurity
  url: security/link-cell-therapies-domain-security.yml
- type: Website
  url: https://linkcelltx.com/
- type: About
  url: https://linkcelltx.com/about/
- type: Team
  url: https://linkcelltx.com/team/
- type: News
  url: https://linkcelltx.com/news/
- type: Contact
  url: https://linkcelltx.com/contact/
- type: PrivacyPolicy
  url: https://linkcelltx.com/privacy-policy/
- type: Careers
  url: https://linkcelltx.com/careers/
- type: Investors
  url: https://linkcelltx.com/investors/
- type: LinkedIn
  url: https://www.linkedin.com/company/linkcelltx/
- type: WellKnown
  url: well-known/link-cell-therapies-well-known.yml
- type: LLMsTxt
  url: llms/link-cell-therapies-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence